Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSI 566

Drug Profile

NSI 566

Alternative Names: hCNS-SC - Neuralstem; HuCNS-SC - Neuralstem; Neural Stem Cells - Neuralstem; NSI-566RSC

Latest Information Update: 01 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuralstem
  • Developer CJ HealthCare; Emory University; Neuralstem; Neuralstem China; University of California, San Diego; University of Freiburg
  • Class Antidementias; Antiparkinsonians; Eye disorder therapies; Neuroprotectants; Nootropics; Stem cell therapies
  • Mechanism of Action Cell replacements; Neurogenesis stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Stroke
  • Phase II Amyotrophic lateral sclerosis
  • Phase I Spinal cord injuries
  • No development reported Alzheimer's disease; Brain injuries; Cerebral palsy; Cognition disorders; Diabetic neuropathies; Huntington's disease; Lysosomal storage diseases; Multiple sclerosis; Optic neuritis; Paraplegia; Parkinson's disease

Most Recent Events

  • 01 Nov 2018 Phase I development in Spinal-cord-injuries is ongoing in USA (Intraspinal, Injection) (Neuralstem website, November 2018)
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Spinal-cord-injuries in USA (Intraspinal, Injection)
  • 28 Sep 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top